By how many US dollars will the value of one Smith+Nephew NYSE ADR (SNN) on 2027-08-31 differ from its value in the retention scenario described by the first alternative?

Current Situation and Baseline Formulation Smith+Nephew shares are currently depressed following a cut to 2026 revenue guidance, which was driven by weak US orthopedic execution (US knee implants -7.2%) and delayed product rollouts 44 sources. Activist Cevian Capital holds a ~14% stake 2 sources, and multiple shareholders are pressing for an orthopedics spin-off 2 sources. Because all alternatives explicitly assume the company remains independent through August 2027, cash takeout premiums are excluded. Consequently, the value differences relative to retaining Deepak Nath (the baseline, exactly $0) depend purely on three mechanisms: operational execution during the critical ongoing LANDMARK/CATALYSTEM launch cycle, the credibility multiple the market assigns to 2027-2028 targets, and the probability of structural value-release (like a portfolio separation) being announced by mid-2027.

Promote CFO John Rogers Promoting Rogers generates a small positive median effect (+$0.36/ADR) with a relatively contained range. Causally, this represents the lowest-disruption transition. Rogers is an experienced executive who recently relocated to the US and has successfully overseen the cost and cash-flow agenda that kept profit guidance intact despite recent revenue misses 3 sources. He would likely rebase the ambitious RISE 2028 targets and might be more open than Nath to portfolio pruning smith-nephew.com. However, the upside is capped because Rogers lacks the direct commercial medtech background required to fix the core US orthopedics problem 2 sources. Furthermore, an internal promotion could be read by activists as continuity rather than decisive change, and moving him opens a critical vacancy in the CFO role right when cost delivery is anchoring the stock. The downside tail (-$2.90) reflects the risk that leadership churn distracts from the vital US knee and hip commercial recovery.

Hire an External Veteran Medtech CEO Bringing in an external veteran yields a higher median difference (+$1.32/ADR) and a substantially fatter right tail (+$6.30/ADR). This intervention brings the highest credibility injection to the market. A veteran medical-device CEO speaks directly to the US commercial and execution failures and represents a clean break from the current regime. Crucially, an outsider arrives with no sunk commitment to Nath’s public rejection of a break-up reuters.com, maximizing the probability of a formal strategic review or business unit spin-off 2 sources. With Cevian on the register as a natural ally, this "shape-up or break-up" optionality provides the single largest potential re-rating catalyst available over a 13-month horizon.

Comparative Risks and Transition Costs Despite the external hire's greater upside, both replacement alternatives carry similar downside risks at the 10th percentile (~-$2.90). An external hire typically involves a 3-6 month transition or gardening leave, creating a strategic vacuum exactly when the orthopedics product cadence needs flawless execution smith-nephew.stylelabs.cloud. Additionally, an external CEO is highly likely to "kitchen-sink" the 2028 RISE targets smith-nephew.com upon arrival in late 2026 or early 2027, taking restructuring charges and resetting margin expectations. While historically the right long-term move to clear the decks, this can severely punish shares in the near term. Therefore, while the external hire offers the most powerful structural upside, both succession branches carry real operational friction and disruption risk compared to the retention baseline.